1. Signaling Pathways
  2. GPCR/G Protein
    Immunology/Inflammation
  3. CXCR
  4. CXCR1 Isoform

CXCR1

 

CXCR1 Related Products (8):

Cat. No. Product Name Effect Purity
  • HY-10198
    Navarixin
    Antagonist 99.13%
    Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly.
  • HY-15251
    Reparixin
    Inhibitor 99.98%
    Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
  • HY-119339
    SX-682
    Inhibitor 98.64%
    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2.
  • HY-15252
    Reparixin L-lysine salt
    Inhibitor 99.93%
    Reparixin L-lysine salt is a potent and specific allosteric inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
  • HY-120878
    CXCR2-IN-2
    Antagonist 98.45%
    CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable CXCR2 antagonist (IC50=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively).
  • HY-12927
    SX-517
    Antagonist
    SX-517 is a dual CXCR2/1 antagonist, containing boronic acid.
  • HY-19519A
    Ladarixin sodium
    Antagonist 99.15%
    Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist.
  • HY-10011
    SCH 563705
    Antagonist 98.20%
    SCH 563705 is a potent and orally available CXCR2 and CXCR1 antagonist, with IC50s of 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively.